New & Emerging Biologic Agents in CRSwNP: Pathophysiology Insights & Patient Selection Criteria
April 28, 2022
April 28, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Integrity Continuing Education, Inc.
This educational activity is supported by an educational grant from GlaxoSmithKline.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity has been designed for allergists, immunologists, nurse practitioners, and physician assistants who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Until recently, the only treatment choices for patients with CRSwNP included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery. Nasal polyposis is typically present in patients with the highest levels of disease severity, and endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery. To address this, novel biologics have been and continue to be evaluated for their impact on CRSwNP, giving clinicians treatment options beyond steroids and surgery for their patients with CRSwNP who are struggling to breathe freely. However, these new options necessitate education on clinical trial results for biologic therapy, criteria that should be used when choosing between biologics and surgery, and patient education in regards to treatment with biologics. These topics will be addressed by expert faculty presenters during this initiative.
Upon completion of this activity, participants should be better able to:
- Review the pathophysiologic/immunogenic molecular drivers of chronic rhinosinusitis that lead to the inflammatory endotypes and relevant comorbidities frequently observed in patients with CRSwNP
- Discuss the differences between currently approved and emerging biologic treatment options for CRSwNP using data from clinical trials and other analyses
- Incorporate an individualized, patient-centric focus based on consensus criteria for patients with CRSwNP when recommending a biologic therapy or endoscopic sinus surgery
Tara F. Carr, MD
Associate Professor of Medicine
Asthma and Airway Disease Research Center
University of Arizona
Joseph K. Han, MD, FARS, FAAAAI
Professor of Otolaryngology & Head and Neck Surgery
Chief, Division of Rhinology & Endoscopic Sinus & Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians Continuing Education
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
- Tara F. Carr, MD
- Advisor/Consultant: AstraZeneca
- Advisory Board: Genentech, GlaxoSmithKline
- Contributor/Reviewer: UpToDate
- Unbranded Disease State Speaker: Novartis, Regeneron
- Joseph K. Han, MD, FARS, FAAAAI
- Consultant: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of April 28, 2022 through April 28, 2023 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.